Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4 expression IMC-C103C has a…
The Breast Cancer Index Test Is the First Biomarker to Predict Treatment Benefit in the SOFT Trial
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #SABCS--Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today…